Review in Clinics in geriatric medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
5 authors.
Lauren LittigDepartment of Neurology, Yale University, 15 York Street, New Haven, CT 06510, USA.
Kevin N ShethDepartment of Neurology, Yale University, 15 York Street, New Haven, CT 06510, USA; Center for Brain and Mind Health, Yale University, 15 York Street, New Haven, CT 06510, USA.
Adam M BrickmanDepartment of Neurology, Columbia University Medical Center, 710 West 168 Street, New York, NY 10032, USA.
Eva A MistryDepartment of Neurology and Rehabilitation Medicine, University of Cincinnati, 260 Stetson Street, Cincinnati, OH 45267, USA.
Adam de HavenonDepartment of Neurology, Yale University, 15 York Street, New Haven, CT 06510, USA; Center for Brain and Mind Health, Yale University, 15 York Street, New Haven, CT 06510, USA. Electronic address: adam.dehavenon@yale.edu.
Funding
Anticoagulation in ICH Survivors for Prevention and Recovery (ASPIRE)U01NS106513 · NINDS · YALE UNIVERSITY · PI Hooman Kamel, Kevin Navin Sheth · 2019 to 2026
$20.6M
Social networks and risk of delayed arrival to the hospital during strokeR01MD016178 · NIMHD · BRIGHAM AND WOMEN'S HOSPITAL · PI Amar Dhand, Kevin Navin Sheth · 2022 to 2026
$3.7M
The Recovery in Stroke Using PAP (RISE UP) StudyR01NR018335 · NINR · YALE UNIVERSITY · PI REDEKER, NANCY S, SHETH, KEVIN NAVIN · 2019 to 2023
$3.4M
Southern New England Partnership In Stroke Research, Innovation and Treatment (SPIRIT)U24NS107215 · NINDS · YALE UNIVERSITY · PI MARK Jay ALBERTS, Karen L Furie · 2018 to 2026
$3.0M
CAPTIVA-MRIUH3NS130228 · NINDS · YALE UNIVERSITY · PI Sepideh Amin-Hanjani, Arindam Rano Chatterjee · 2025 to 2026
$2.8M
Blood Pressure Variability and Ischemic Stroke Outcome (BP-VISO)R01NS130189 · NINDS · YALE UNIVERSITY · PI Adam H. de Havenon · 2023 to 2026
$2.0M
CAPTIVA-MRIUG3NS130228 · NINDS · YALE UNIVERSITY · PI AMIN-HANJANI, SEPIDEH, CHATTERJEE, ARINDAM R. · 2023 to 2023
$1.9M
Improved glyburide therapy via acid- triggered release functional nanoparticles and therapeutic imagingR01NS110721 · NINDS · YALE UNIVERSITY · PI SHETH, KEVIN NAVIN, ZHOU, JIANGBING · 2019 to 2023
$1.9M
Yale-METRO Metropolitan Emergency Trial netwoRK to advance patient OutcomesU24NS129500 · NINDS · YALE UNIVERSITY · PI Gail D'Onofrio, Kevin Navin Sheth · 2023 to 2026
$1.7M
Yale Clinical Site: Investigations For Improved Neurological Treatments at Yale (INFINITY)U24NS107136 · NINDS · YALE UNIVERSITY · PI SHETH, KEVIN NAVIN, SPUDICH, SERENA S · 2018 to 2022
$1.7M
Treatment Targets for Inflamed Intracranial Atherosclerosis on Vessel Wall MRIK23NS105924 · NINDS · YALE UNIVERSITY · PI DE HAVENON, ADAM H. · 2019 to 2023
This review explores the extensive evidence linking hypertension with vascular cognitive impairment and dementia, emphasizing its role as a treatable risk factor. Drawing on observational data, it will elucidate how the chronicity of hypertension at different life stages amplifies cognitive decline risk. It explores the mechanisms underlying hypertension's association with dementia, assesses the neuroprotective properties of antihypertensive therapy, and evaluates novel blood pressure metrics and monitoring methods for their diagnostic and therapeutic potential in dementia management.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Blood Pressure and Cognitive Function in Older Adults. · full record | OpenQuestion